Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 403

Implausibility of radical life extension in humans in the twenty-first century

Abstract Over the course of the twentieth century, human life expectancy at birth rose in high-income nations by approximately 30 years, largely driven by advances in public health and medicine.

In the twentieth century, human life expectancy rose dramatically. Based on the past three decades of observed mortality in the eight countries with the longest-lived populations and in Hong Kong and the United States, Olshansky et al. propose that, without medical breakthroughs that slow aging, radical lifespan extension is implausible in this century.

Gut Microbiome Influences Location of Immune Cells, study finds

Researchers at the Experimental and Clinical Research Center of Max Delbrück Center and Charité — Universitätsmedizin Berlin (ECRC) have found that different anatomical sections of the gastrointestinal tracts of mice carry different compositions of microbial communities. Moreover, the specific makeup of the microbiota can influence the type and abundance of immune cells in any particular region. The study, which was published in Gut Microbes, maps the complex spatial organization of immune cells and microbial communities, providing a tool for studying the interaction between gut microbes and inflammatory diseases.

Previous research has hinted at the existence of “hotspots” along the GI tract where specific immune cells and microbes might interact more intensely.

But no one had systematically investigated this across the entire gut, says Dr. Hendrik Bartolomaeus, in the Immune-Microbial Dynamics in Cardiorenal Disease lab of Dr. Nicola Wilck, and an author of the study.

Researchers Say Quantum Machine Learning, Quantum Optimization Could Enhance The Design And Efficiency of Clinical Trials

Despite the promising findings, the study acknowledges several limitations of quantum computing. One of the primary challenges is hardware noise, which can reduce the accuracy of quantum computations. Although error correction methods are improving, quantum computing has not yet reached the level of fault tolerance needed for widespread commercial use. Additionally, the study notes that while quantum computing has shown promise in PBPK/PD modeling and site selection, further research is needed to fully realize its potential in these areas.

Looking ahead, the study suggests several future directions for research. One of the key areas for improvement is the integration of quantum algorithms with existing clinical trial infrastructure. This will require collaboration between researchers, pharmaceutical companies and regulators to ensure that quantum computing can be effectively applied in real-world clinical settings. Additionally, the study calls for more work on developing quantum algorithms that can handle the inherent variability in biological data, particularly in genomics and personalized medicine.

The research was conducted by a team from several prominent institutions. Hakan Doga, Aritra Bose, and Laxmi Parida are from IBM Research and IBM Quantum. M. Emre Sahin is affiliated with The Hartree Centre, STFC, while Joao Bettencourt-Silva is based at IBM Research, Dublin, Ireland. Anh Pham, Eunyoung Kim, Anh Pham, Eunyoung Kim and Alan Andress are from Deloitte Consulting LLP. Sudhir Saxena and Radwa Soliman are from GNQ Insilico Inc. Jan Lukas Robertus is affiliated with Imperial College London and Royal Brompton and Harefield Hospitals and Hideaki Kawaguchi is from Keio University. Finally, Daniel Blankenberg is from the Lerner Research Institute, Cleveland Clinic.

Scientists Made a Breakthrough Using CRISPR for Autoimmune Diseases

According to the National Institute of Environmental Health Services, nearly 50 million Americans are currently living with an autoimmune condition. It’s the third-largest category of diseases affecting the nation, according to the agency. Doctors and scientists have been using a number of promising CRISPR treatments to address some of these conditions; now, the results of a new study in China could offer a way to make these treatments even more widely available.

As Nature‘s Smriti Mallapaty explains, the study focused on three people whose treatments were created using donor cells as opposed to cells taken from the patients themselves. This is significant because the prospect of using donor cells allows for CRISPR treatments to be developed in larger quantities — something that could make a big difference in a lot of people’s lives around the world.

Mallapaty describes the three patients in the study as having “severe autoimmune conditions.” One of them, a man in his fifties with systemic sclerosis, said that he started feeling better within a few days, and was able to resume working two weeks after the treatment. This particular study isn’t the only one of its kind — Nature‘s reporting mentions that another trial was subsequently conducted with more patients, while another doctor is leading a similar study using donor cells to treat lupus.

Like Father, Like Daughter

Mouse study finds fathers on unhealthy diets can cause cardiovascular disease in their daughters. When they become fathers, men who have an unhealthy, high-cholesterol diet can cause increased risk of cardiovascular disease, or CVD, in their daughters, a University of California, Riverside-led mouse study has found.

The research, published in the journal JCI Insight, is the first to demonstrate this result seen only in female offspring.

CVD, the leading cause of death globally, is a group of disorders that affects the heart and blood vessels. Hypertension (high blood pressure) is a leading risk factor for CVD. In the United States, nearly 703,000 people died in 2022 from heart disease, the equivalent of one in every five deaths.

Engineers develop a bendable, programmable, non-silicon microprocessor that requires only 6 mW of power

A team of microchip engineers at Pragmatic Semiconductor, working with a pair of colleagues from Harvard University and another from Qamcom, has developed a bendable, programmable, non-silicon 32-bit RISC-V microprocessor. Their research is published in the journal Nature.

Over the past several years, hardware manufacturers have been developing bendable microprocessors for use in . A bendable device with bendable components would allow for the creation of 24-hour sensors that could be applied to any part of the body.

For this new project, the research team developed an inexpensive circuit board that could be bent around virtually any curved object. The material was made using indium gallium zinc oxide instead of the more rigid silicon.